Pacira BioSciences Inc (NASDAQ: PCRX)’s stock price has plunge by 3.84relation to previous closing price of 26.03. Nevertheless, the company has seen a 15.86% surge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-30 that LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before March 14, 2025.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
Additionally, the 36-month beta value for PCRX is 0.80. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 rating it as “hold,” and 1 rating it as “sell.”
The public float for PCRX is 44.70M and currently, short sellers hold a 12.18% ratio of that float. The average trading volume of PCRX on January 30, 2025 was 779.33K shares.
PCRX’s Market Performance
PCRX’s stock has seen a 15.86% increase for the week, with a 37.56% rise in the past month and a 57.79% gain in the past quarter. The volatility ratio for the week is 6.75%, and the volatility levels for the past 30 days are at 5.87% for Pacira BioSciences Inc The simple moving average for the past 20 days is 23.51% for PCRX’s stock, with a 30.34% simple moving average for the past 200 days.
Analysts’ Opinion of PCRX
Truist, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $8, previously predicting the price at $30. The rating they have provided for PCRX stocks is “Sell” according to the report published on August 13th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to PCRX, setting the target price at $14 in the report published on August 12th of the previous year.
PCRX Trading at 36.21% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.52% of loss for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 6.75%, as shares surge +40.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.25% upper at present.
During the last 5 trading sessions, PCRX rose by +13.84%, which changed the moving average for the period of 200-days by -1.01% in comparison to the 20-day moving average, which settled at $21.86. In addition, Pacira BioSciences Inc saw 43.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from SLONIN JONATHAN, who sale 879 shares at the price of $18.40 back on Jan 06 ’25. After this action, SLONIN JONATHAN now owns 93,444 shares of Pacira BioSciences Inc, valued at $16,174 using the latest closing price.
SLONIN JONATHAN, the Officer of Pacira BioSciences Inc, proposed sale 879 shares at $18.40 during a trade that took place back on Jan 06 ’25, which means that SLONIN JONATHAN is holding shares at $16,174 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.68 for the gross margin
The net margin for Pacira BioSciences Inc stands at -0.13. The total capital return value is set at -0.05. Equity return is now at value -11.48, with -5.94 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 0.86. The interest coverage ratio of the stock is -4.34.
Currently, EBITDA for the company is 157.58 million with net debt to EBITDA at 17.39. When we switch over and look at the enterprise to sales, we see a ratio of 2.4. The receivables turnover for the company is 6.9for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
In conclusion, Pacira BioSciences Inc (PCRX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
